Table 1 Patients characteristics and demographics
All patients (n = 92) | No organ damage SLICC/ACR-DI = 0 (n = 42) | Organ damage SLICC/ACR-DI ≥1 (n = 50) | |
|---|---|---|---|
Age, median (range) years | 48 (22 to 84) | 43 (22 to 79) | 60 (24 to 84) |
Female gender, n (%) | 81 (88%) | 37 (88%) | 44 (88%) |
Disease duration, median (range) years | 14 (0 to 51) | 9 (0 to 29) | 19 (0 to 51) |
SLEDAI, median (range) | 2 (0 to 16) | 2 (0 to 16) | 1 (0 to 13) |
SLICC/ACR-DI median (range) | 1 (0 to 8) | 0 | 2 (1 to 8) |
PMN 109/L median (range) | 4.0 (<0.1 to 11) | 3.6 (1.4 to 9.8) | 4.7 (<0.1 to 11) |
Disease manifestations at time of sampling, n | |||
Lupus headache | 1 | 0 | 1 |
Arthritis | 10 | 5 | 5 |
Kidney involvement (urinary cast, hematuria, proteinuria, or pyuria) | 6 | 3 | 3 |
Rash | 4 | 2 | 2 |
Alopecia | 2 | 1 | 1 |
Low complement (C3 or C4) | 36 | 21 | 15 |
Anti-double stranded DNA antibodies | 18 | 10 | 8 |
Leukopenia | 7 | 4 | 3 |
Treatment | |||
Prednisone, % (median dose of treated patients) | 53 (5 mg) | 60 (5 mg) | 50 (6.25 mg) |
Hydroxychloroquine, % (n) | 59 (54) | 69 (29) | 50 (25) |
Chloroquine phosphate, % (n) | 2 (2) | 2 (1) | 2 (1) |
Azathioprine, % (n) | 24 (22) | 29 (12) | 20 (10) |
Mycophenolate mofetil%, (n) | 12 (11) | 14 (6) | 10 (5) |
Rituximab, % (n) | 2 (2) | 0 (0) | 4 (2) |
Methotrexates, % (n) | 4 (4) | 5 (2) | 4 (2) |
Cyclosporine A, % (n) | 2 (2) | 0 (0) | 4 (2) |